Post-earnings recap
Reported
Thu, Jul 30, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Apellis Pharmaceutical faced challenges with its earnings per share, missing expectations. However, the stock reacted positively, rising by 2.87%, likely due to investor optimism about the company's future clinical programs despite the EPS miss. The lack of revenue data and guidance may leave some investors cautious moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.57 | N/A | -20.86% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to ongoing development and future opportunities.
Management did not provide specific revenue guidance for the upcoming quarters.
The company remains focused on advancing its clinical programs despite the EPS miss.